Friday Satellite Symposia
Lymphoid Leukemias, ALL, Education, Diseases, Treatment Considerations, Lymphoid Malignancies, Adverse Events
Room 30
(San Diego Convention Center)
Chair:
Ola Landgren, ARRAY(0x102d5f98)
Disclosures:
Landgren: Takeda: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Membership on independent data monitoring committees; Amgen: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Membership on independent data monitoring committees; Merck: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Membership on independent data monitoring committees; Theradex: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Membership on independent data monitoring committees.; Adaptive: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Membership on independent data monitoring committees; Celgene: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Membership on independent data monitoring committees; Janssen: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Membership on independent data monitoring committees.
Speakers:
Katja C. Weisel, MD, Department of Oncology, Hematology and BMT, University Medical Center of Hamburg-Eppendorf
and
Cristina Gasparetto, MD, Duke University Medical Center
Disclosures:
Weisel: Adaptive Biotechnologies: Consultancy, Honoraria; Sanofi: Consultancy, Honoraria, Other: Research grant to institution; Takeda: Consultancy, Honoraria; Pfizer: Consultancy, Honoraria; Roche Pharma: Consultancy, Honoraria; AstraZeneca: Honoraria; Novartis: Honoraria; Amgen: Consultancy, Honoraria, Other: Research grant to institution; AbbVie: Other: Research grant to institution; Bristol Myers Squibb/Celgene: Consultancy, Honoraria, Other: Research grant to institution; BeiGene: Consultancy, Honoraria; Karyopharm: Consultancy, Honoraria; GlaxoSmithKline: Consultancy, Honoraria, Other: Research grant to institution; Janssen: Consultancy, Honoraria, Other: Research grant to institution; Menarini: Consultancy, Honoraria; Oncopeptides: Consultancy, Honoraria; Stemline: Honoraria; Regeneron: Consultancy.
On Demand program will be available here December 7, 2024.
Access Program Here
The live portion of this activity will be presented as a 2.0-hour Friday Satellite Symposium (FSS). The activity is designed to highlight and test participants on the most clinically relevant data in NDMM, provide expert guidance on the interpretation of core concepts, and forecast the clinical impact of recent data sets. The activity will integrate a series of How We Do It® panel discussions alongside didactic presentations. To further enhance the integration of recent data into practice, the program will feature an interactive question-and-answer session with faculty throughout the activity to emphasize areas of educational need, highlighting areas of debate, and illustrating the application of new data in defined clinical situations. To further enhance the integration of recent data into practice, the program will feature an interactive question-and-answer session between the faculty and attendees to emphasize areas of educational need, highlight areas of debate, and illustrate the application of new data in defined clinical situations.
denotes an abstract that is clinically relevant.
denotes that this is a recommended PHD Trainee Session.
denotes that this is a ticketed session.